Alzheimer’s study gets funding boost
Tuesday, 14 October, 2008
Pfizer Australia has signed up to partner the CSIRO for its Alzheimer’s disease cluster study.
The Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) is designed to better understand the causes of Alzheimer’s disease and to discover a method for early diagnosis.
The study is a multi-organisational initiative and has so far recruited over 1000 volunteers. They are being investigated by neuro-imaging, clinical and cognitive testing, blood biomarker samples and health and lifestyle data.
The partnership with Pfizer is worth $1.1 million over three years and will see a panel of biomarkers tested against the volunteer group.
The study’s leader, University of Melbourne’s Professor David Aims, said the main aim of the project was the Holy Grail of Alzheimer’s research – a blood test.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
